Is Mind Medicine a Good Psychedelic Stock to Buy?

: MNMD | Mind Medicine (MindMed) Inc. News, Ratings, and Charts

MNMD – Even as COVID-19 related restrictions ease, mental health issues are on the rise. Consequently, Mind Medicine (MNMD) is attracting investors’ attention due to its drug development pipeline of innovative treatments that are based on psychedelic substances. But, given that the company’s drugs are still in their developmental stage, is it wise to bet on the stock now? Let’s find out.

Psychedelic medicine biotech company Mind Medicine (MindMed) Inc. (MNMD - Get Rating) made its debut on  Nasdaq Capital Market on April 27, 2021 while retaining its listing on the Neo Exchange Inc. under the symbol MMED. The company didn’t have a great market debut as its shares fell 29% on the first day of trading on the Nasdaq. And the stock has lost 25.6% over the past month to close Friday’s trading session at $3.40.

While the demand for treatments based on psychedelic substances is growing because mental health issues are on the rise despite the easing of restrictions related to the COVID-19 pandemic, MNMD’s psychedelic inspired medicines are still in their developmental stage. Also, its net and comprehensive loss for fiscal first quarter ended March 31, 2021 came in at $14 million.

MNMD still has a long way to go to complete the development of its products, so its near-term prospects look bleak. As the company’s co-founder and CEO JR Rahn told Yahoo Finance, “These are still very early innings for us.”

Click here to checkout our Healthcare Sector Report for 2021

Here’s what I think could shape MNMD’s performance in the near term:

Psychedelic Drugs Yet to be Widely Accepted

According to Data Bridge Market Research, the psychedelic drugs market is expected to reach $6,859.95 million by 2027, growing at a 16.3% CAGR. This assumes that the rising prevalence of mental depression and anxiety and the availability of off-label drugs are expected to drive an increasing demand for  psychedelic drugs. However, the market faces some challenges, such as uncertainty surrounding  FDA approval, the early stage in the lifecycle of the psychedelics industry, and a stigma associated with the use of psychedelic drugs, among others. As a result, MNMD may continue  struggling for some time.

Most of MNMD’s Products Still in Developmental Stage

MNMD is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances, such as Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. Its LSD experiential therapy, named Project Lucy, is in Phase 2A development, while its 18-MC substance use disorders project is in its Phase 1 development stage. Its LSD Microdosing Adult ADHD is also in Phase 1 development. So, it will likely take the company a significant period to generate revenues from the deployment of  these drugs.

Selling Shares to Fund Growth Activities

MNMD announced on March 9, 2021 that it had closed its offering of  6 million units to raise  gross proceeds of CAD$19.5 million ($16.15 million). Following the offering’s closing, its cash in hand has increased to CAD$205.2 million ($162.0 million).

MNMD is expected to use proceeds from the offering for general working capital and for further investment in Project Lucy, the Microdose LSD Program and Project Albert, which is now integrated with MNMD’s most recent technology acquisition, HealthMode, to build a comprehensive mental health platform to deploy psychedelics medicines.

POWR Ratings Reflect Bleak Prospects

MNMD has an overall D rating, which equates to Sell in our POWR Ratings system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree. 

Our proprietary rating system also evaluates each stock based on eight different categories. Among  these categories, MNMD has a D grade for Quality, which is in sync with its negative ROE and ROTC.

The stock has a D grade for Momentum, which is consistent with its 25.6% loss over the past month. It has a D grade for Stability also. 

Beyond what we’ve stated above, we’ve also given MNMD grades for Growth, Value and Sentiment. Get all the MNMD ratings here. MNMD is ranked #268 out of 491 stocks in the Biotech industry.

Better than MNMD: Click here to access 27 top-rated stocks in the same industry.

Bottom Line

MNMD is an emerging player in the psychedelic drug space, but it still has a long way to go. Its EPS is expected to remain negative in its fiscal years 2021 and 2022 because its drugs are still in their early development stage. So, we think it’s wise to avoid the stock now.  

Click here to checkout our Healthcare Sector Report for 2021

Want More Great Investing Ideas?

9 “Must Own” Growth Stocks for 2021

Top 10 Value Stocks

5 Ways to Beat the S&P 500

3 Signs of a NEW Stock Market Bubble


MNMD shares were trading at $3.14 per share on Tuesday morning, down $0.26 (-7.65%). Year-to-date, MNMD has gained 2.95%, versus a 12.78% rise in the benchmark S&P 500 index during the same period.


About the Author: Manisha Chatterjee


Since she was young, Manisha has had a strong interest in the stock market. She majored in Economics in college and has a passion for writing, which has led to her career as a research analyst. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
MNMDGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


Stock Market Update: It’s Complicated!

The S&P 500 (SPY) may have bounced 17% from recent lows, but the outlook for stocks from here is...in a word...COMPLICATED. Read on to get Steve Reitmeister full market outlook and trading plan for this complicated market environment.

Becoming More Bullish on Stocks, But...

Stocks are on a roll with the S&P 500 (SPY) up more than 10% from the recent lows. Before you start getting too giddy, you should read this updated market outlook and trading plan Steve Reitmeister.

Stock Market Held Hostage

Uncertainty is the term most often applied to this stock market. Uncertainty over tariffs. Uncertainty of whether the S&P 500 (SPY) will fall into bear territory. Uncertainty over what happens next. Steve Reitmeister dives into the uncertainty to make sense of the market in this week’s commentary...

Stock Market Standing on the 50 Yard Line

Steve Reitmeister contemplates where the stock market stands now and what happens next in trying to stay on the right side of the market action. One path points to bear and one to new highs for the S&P 500 (SPY). Which will it be?

Bear or Bull Market?

The S&P 500 is on the brink of bear market territory...but that outcome is not a given at this time. Steve Reitmeister shares insights gleaned from his 45 years of investing to shine a light on current conditions along with his top picks...

Read More Stories

More Mind Medicine (MindMed) Inc. (MNMD) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All MNMD News